Open communication with your healthcare team about progress ensures rapid adjustment or pivot to alternative strategies if needed
Retatrutide and tirzepatide are two novel incretin mimetics with shared benefits for clinical research, including: Weight management Glycemic control Cardiovascular health Retatrutide is a triple-hormone-receptor agonist currently being explored as a potential treatment for weight loss
Retrieved from Liu, S., Wang, X., Zheng, Q., et al
Its formulation is designed for mucoadhesion, which could increase contact time with the sublingual mucosa
Glucagon receptor the receptor unique to retatrutide among current incretin-class research peptides
Most protocols balance injection volume against precision, using 1-2ml for most reconstitutions